Piper Jaffray Remains Negative on Sarepta (SRPT), 'Unable to Handicap Chances for AA'
Tweet Send to a Friend
Piper Jaffray analyst Edward Tenthoff maintained an Underperform rating and $6 price target on Sarepta Therapeutic (NASDAQ: SRPT) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
